RET codon 804 mutations in multiple endocrine neoplasia 2: Genotype-phenotype correlations and implications in clinical management

Clinical Genetics

Volumn 79, Issue 1, 2011, Pages 1-16

  Mukherjee, S ^a   Zakalik, D ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Codon 804; Medullary thyroid cancer; Multiple endocrine neoplasia; Phenotype; RET

Indexed keywords

CYSTEINE; PROTEIN RET;

ALLELE; CODON; DISEASE COURSE; EXON; GENE ACTIVATION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE STRUCTURE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HOMOZYGOSITY; HUMAN; MULTIPLE ENDOCRINE NEOPLASIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CODON; CYSTEINE; FEMALE; GENETIC ASSOCIATION STUDIES; GERM-LINE MUTATION; HUMANS; INFANT; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PENETRANCE; POINT MUTATION; PROTO-ONCOGENE PROTEINS C-RET; PROTO-ONCOGENES; THYROID NEOPLASMS; YOUNG ADULT;

EID: 78649990359     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2010.01453.x     Document Type: Review

References (127)

1. Mulligan LM, Kwok JB, Healey CS et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993: 363: 458-460.
2. Donis-Keller H, Dou S, Chi D et al. Mutations in the RET proto-oncogene are associated with MEN2A and FMTC. Hum Mol Genet 1993: 2: 851-856.
3. Pachnis V, Mankoo B, Costantini F. Expression of the c-ret proto-oncogene during mouse embryogenesis. Development 1993: 119: 1005-1017.
4. Zbuk KM, Eng C. Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer 2007: 7 (1): 35-45.
5. Eng C, Clayton D, Schuffenecker I et al. The relationship between specific ret proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996: 276: 1575-1579.
6. Ponder BAJ, Ponder MA, Coffey R et al. Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet 1988: 1: 397-401.
7. Easton DF, Ponder MA, Cummings T et al. The clinical and screening age-at onset distribution for MEN-2 syndrome. Am J Hum Genet 1989: 44: 208-215.
8. Borst MJ, VanCamp JM, Peacock ML et al. Mutational analysis of multiple endocrine neoplasia type 2A associated with Hirschsprung's disease. Surgery 1995: 117: 386-391.
9. Verga U, Fugazzola L, Cambiaghi S et al. Frequent association between MEN2A and cutaneous lichen amyloidosis. Clin Endocrinol (Oxf) 2003: 59: 156-161.
10. Lora MS, Waguespack SG, Moley JF et al. Adrenal ganglioneuromas in children with multiple endocrine neoplasia type 2: a report of two cases. J Clin Endocrinol Metab 2005: 90 (7): 4383-4387.
11. Takai S, Kinoshita S, Tanaka F et al. Prominent corneal nerves in patients with multiple endocrine neoplasia type 2A: diagnostic implications. World J Surg 1992: 16 (4): 620-623.
12. De Groot JW, Links TP, Plukker JT et al. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 2006: 27: 535-560.
13. Machens A, Gimm O, Hinze R et al. Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J Clin Endocrinol Metab 2001: 86 (3): 1104-1109.
14. Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 1985: 42: 581-588.
15. Pasini B, Hofstra RM, Yin L et al. The physical map of the human RET proto-oncogene. Oncogene 1995: 11 (9): 1737-1743.
16. Takahashi M, Buma Y, Iwamoto T et al. Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 1998: 3: 571-578.
17. Santoro M, Carlomagno F, Romano A et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995: 267: 381-383.
18. Asai N, Iwashita T, Matsuyama M et al. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 1995: 15: 1613-1619.
19. Borrello MG, Smith DP, Pasini B et al. RET activation by germline MEN2A and MEN2B mutations. Oncogene 1995: 11: 2419-2427.
20. Eng C, Mulligan LM, Smith DP et al. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf) 1995: 43: 123-127.
21. Plaza Menacho I, Koster R, Van Der Sloot AM et al. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor. Cancer Res 2005: 65: 1729-1737.
22. Pasini A, Geneste O, Legrand P et al. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain. Oncogene 1997: 15: 393-402.
23. Frank-Raue K, Rondot S, Schulze E et al. Change in the spectrum of RET mutations diagnosed between 1994 and 2006. Clin Lab 2007: 53 (5-6): 273-282.
24. Machens A, Dralle H. Familial prevalence and age of RET germline mutations: implications for screening. Clin Endocrinol (Oxf) 2008: 69 (1): 81-87.
25. Kouvaraki MA, Shapiro SE, Perrier ND et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 2005: 15 (6): 531-544.
26. Dvorakova S, Vaclavikova E, Duskova J et al. Exon 5 of the RET proto-oncogene: a newly detected risk exon for familial medullary thyroid carcinoma, a novel germline mutation Gly321Arg. J Endocrinol Invest 2005: 28: 905-909.
27. Mulligan LM, Eng C, Healey CS et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 1994: 6: 70-74.
28. Bolino A, Schuffenecker I, Luo Y et al. RET mutations in exons 13 and 14 of FMTC patients. Oncogene 1995: 10: 2415-2419.
29. Berndt I, Reuter M, Saller B et al. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 1998: 83: 770-774.
30. Fink M, Weinhausel A, Niederle B et al. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. Int J Cancer 1996: 69: 312-316.
31. Fattoruso O, Quadro L, Libroia A et al. A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET proto-oncogene in two families affected by familial medullary thyroid carcinoma. Hum Mutat 1998: S167-S171.
32. Shannon KE, Gimm O, Hinze R et al. Germline V804M mutation in the RET proto-oncogene in two apparently sporadic cases of MTC presenting in the seventh decade of life. J Endocr Genet 1999: 1: 39-46.
33. Nillson O, Tisell L, Jansson S et al. Adrenal and extra adrenal pheochromocytomas in a family with germline RET V804L mutation, letter to the editor. JAMA 1999: 281: 1587-1588.
34. Jimenez C, Habra MA, Huang SC et al. Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation. J Clin Endocrinol Metab 2004: 89: 4142-4145.
35. Yip L, Cote GJ, Shapiro SE et al. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 2003: 138: 409-416.
36. Machens A, Niccoli-Sire P, Hoegel J et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 2003: 349: 1517-1525.
37. Frank-Raue F, Frank-Raue K. Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management. Hormones (Athens) 2009: (1): 23-28.
38. Decker RA, Peacock ML, Watson P. Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation. Hum Mol Genet 1998: 7: 129-134.
39. Vaclavikova E, Dvorakova S, Sykorova V et al. RET mutation Tyr791Phe: the genetic cause of different diseases derived from neural crest. Endocrine (in press).
40. Rothberg AE, Raymond VM, Gruber SB et al. Familial medullary thyroid carcinoma associated with cutaneous lichen amyloidosis. Thyroid 2009: 19 (6): 651-655.
41. Brandi ML, Gagel RF, Angeli A et al. Consensus: guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001: 86: 5658-5671.
42. Kloos RT, Eng C, Evans DB et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009: 19 (6): 565-612.
43. Schuffenecker I, Billaud M, Calender A et al. RET proto-oncogene mutations in French MEN 2A and FMTC families. Hum Mol Genet 1994: 3 (11): 1939-1943.
44. Frank-Raue K, Höppner W, Frilling A et al. Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group. J Clin Endocrinol Metab 1996: 81 (5): 1780-1783.
45. Landsvater RM, Jansen RP, Hofstra RM et al. Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A. Hum Genet 1996: 97 (1): 11-14.
46. Sánchez B, Robledo M, Biarnes J et al. High prevalence of the C634Y mutation in the RET proto-oncogene in MEN 2A families in Spain. J Med Genet 1999: 36 (1): 68-70.
47. Niccoli-Sire P, Murat A, Rohmer V et al. Familial medullary thyroid carcinoma with noncysteine RET mutations: pheontype-genotype relationship in a large series of patients. J Clin Endocrinol Metab 2001: 86: 3746-3753.
48. Machens A, Holzhausen HJ, Thanh PN et al. Malignant progression from C-cell hyperplasia to medullary thyroid carcinoma in 167 carriers of RET germline mutations. Surgery 2003: 134 (3): 425-431.
49. Elisei R, Romei C, Cosci B et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 2007: 92 (12): 4725-4729.
50. Pinna G, Orgiana G, Riola A et al. RET proto-oncogene in Sardinia: V804M is the most frequent mutation and may be associated with FMTC=MEN-2A phenotype. Thyroid 2007: 17: 101-104.
51. Marrosu MG, Lai M, Cocco E et al. Genetic factors and the founder effect explain familial MS in Sardinia. Neurology 2002: 58: 283-288.
52. Richards ML. Thyroid cancer genetics: multiple endocrine neoplasia type 2, non-medullary familial thyroid cancer, and familial syndromes associated with thyroid cancer. Surg Oncol Clin N Am 2009: 18 (1): 39-52.
53. Heptulla RA, Schwartz RP, Bale AE et al. Familial medullary thyroid carcinoma: presymptomatic diagnosis and management in children. J Pediatr 1999: 135: 327-331.
54. Lombardo F, Baudin E, Chiefari E et al. Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804. J Clin Endocrinol Metab 2002: 87: 1674-1680.
55. Lecube A, Hernandez C, Oriola J et al. V804M RET mutation and familial medullary thyroid carcinoma: report of a large family with expression of the disease only in the homozygous gene carriers. Surgery 2002: 131: 509-514.
56. Frohnauer M, Decker R. Update on the MEN 2A c804 RET mutation. Is prophylactic thyroidectomy indicated? Surgery 2000: 128: 1052-1058.
57. Feldman GL, Edmonds MW, Ainsworth PJ et al. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG-ATG) mutation. Surgery 2000: 128: 93-98.
58. Learoyd DL, Gosnell J, Elston MS et al. Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations. Clin Endocrinol (Oxf) 2005: 63: 636-641.
59. Patócs A, Klein I, Szilvasi A et al. Genotype-phenotype correlations in Hungarian patients with hereditary medullary thyroid cancer. Wien Klin Wochenschr 2006: 118 (13-14): 417-421.
60. Gosnell JE, Sywak MS, Sidhu SB et al. New era: prophylactic surgery for patients with multiple endocrine neoplasia-2a. ANZ J Surg 2006: 76 (7): 586-590.
61. Lesueur F, Cebrian A, Cranston A et al. Germline homozygous mutations at codon 804 in the RET protooncogene in medullary thyroid carcinoma/multiple endocrine neoplasia type 2A patients. J Clin Endocrinol Metab 2005: 90 (6): 3454-3457.
62. Gagel RF, Jackson CE, Block MA et al. Age related probability of development of hereditary medullary thyroid carcinoma. J Pediatr 1982: 101: 941-946.
63. Gagel RF, Tashjian AH, Cummings T et al. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2A. An 18-year experience. N Engl J Med 1988: 318: 478-484.
64. Lips CJM, Landsvater RM, Hoppener JWM et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994: 331: 828-835.
65. Modigliani E, Cohen R, Campos JM et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. Clin Endocrinol (Oxf) 1998: 48: 265-273.
66. Scacheri P, Crabree J, Kenndy A et al. V804 RET mutation in MEN2A: first report. J Int Med 2004: 255: 712. (Abstract).
67. Bugalho MJ, Domingues R, Santos JR et al. Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre. Surgery 2007: 141 (1): 90-95.
68. Recasens M, Oriola J, Fernandez-Real JM et al. Asymptomatic bilateral adrenal pheochromocytomas in a patient with a germ-line V804M mutation in the RET proto-oncogene. Clin Endocrinol 2007: 67: 29-33.
69. Gibelin H, Bezieau S, Misso C et al. Germline RET V804M mutation associated with multiple endocrine neoplasia type 2A. Br J Surg 2004: 91 (11): 1458-1459.
70. Kinoshita S, Tanaka F, Ohashi Y et al. Incidence of prominent corneal nerves in multiple endocrine neoplasia type 2A. Am J Ophthalmol 1991: 111 (3): 307-311.
71. Kasprzak L, Nolet S, Gaboury L et al. Familial medullary thyroid carcinoma and prominent corneal nerves associated with the germline V804M and V778I mutations on the same allele of RET. J Med Genet 2002: 38: 784-787.
72. Cranston AN, Carniti C, Oakhill K et al. RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B. Cancer Res 2006: 66 (20): 10179-10187.
73. Miyauchi A, Futami H, Hai N et al. Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. Jpn J Cancer Res 1999: 90 (1): 1-5.
74. Robledo M, Gil L, Pollan M et al. Polymorphisms G691S/ S904S of RET as genetic modifiers of MEN 2A. Cancer Res 2003: 63: 1814-1817.
75. Cebrian A, Lesueur F, Martin S et al. Polymorphisms in the initiators of RET (rearranged during transfection) signalling pathway and susceptibility to sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 2005: 90: 6268-6274.
76. Fugazzola L, Muzza M, Mian C et al. RET genotypes in sporadic medullary thyroid cancer: studies in a large Italian series. Clin Endocrinol (Oxf) 2008: 69 (3): 418-425.
77. Cardot-Bauters C, Leteurtre E, Leclerc L et al. Does the RET variant G691S influence the features of sporadic medullary thyroid carcinoma? Clin Endocrinol 2008: 69: 506-510.
78. Gimm O, Ukkat J, Niederle BE et al. Timing and extent of surgery in patients with familial medullary thyroid carcinoma/multiple endocrine neoplasia 2A-related RET mutations not affecting codon 634. World J Surg 2004: 28 (12): 1312-1316.
79. Machens A, Schneyer U, Holzhausen HJ et al. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 2005: 90 (4): 2029-2034.
80. Machens A, Lorenz K, Dralle H. Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels. Ann Surg 2009: 250 (2): 305-310.
81. Høie J, Heimdal K, Nesland JM et al. Prophylactic thyroidectomy in carriers of RET oncogene mutation carriers. Tidsskr Nor Laegeforen 2000: 120 (27): 3249-3252.
82. Hansen HS, Torring H, Godballe C et al. Is thyroidectomy necessary in RET mutations carriers of the familial medullary thyroid carcinoma syndrome?. Cancer 2000: 89 (4): 863-867.
83. Vestergaard P, Vestergaard EM, Brockstedt H et al. Codon Y791F mutations in a large kindred: is prophylactic thyroidectomy always indicated?. World J Surg 2007: 31 (5): 996-1001. Discussion.
84. Jindrichová S, Vcelák J, Vlcek P et al. Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic. J Endocrinol 2004: 183 (2): 257-265.
85. Paszko Z, Sromek M, Czetwertynska M et al. The occurrence and the type of germline mutations in the RET gene in patients with medullary thyroid carcinoma and their unaffected kindred's from Central Poland. Cancer Invest 2007: 25 (8): 742-749.
86. Decker RA, Peacock ML. Update on the profile of multiple endocrine neoplasia type 2a RET mutations. Practical issues and implications for genetic testing. Cancer Suppl 1997: 80 (3): 557-568.
87. Skinner MA. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 2005: 353: 1105-1113.
88. González B, Salcedo M, Medrano ME et al. RET oncogene mutations in medullary thyroid carcinoma in Mexican families. Arch Med Res 2003: 34 (1): 41-49.
89. Takami H. Medullary thyroid carcinoma and multiple endocrine neoplasia type 2. Endocr Pathol 2003: 14 (2): 123-131.
90. Lau GS, Lang BH, Lo CY et al. Prophylactic thyroidectomy in ethnic Chinese patients with multiple endocrine neoplasia type 2A syndrome after the introduction of genetic testing. Hong Kong Med J 2009: 15 (5): 326-331.
91. Zhou Y, Zhao Y, Cui B et al. RET proto-oncogene mutations are restricted to codons 634 and 918 in mainland Chinese families with MEN2A and MEN2B. Clin Endocrinol (Oxf) 2007: 67 (4): 570-576.
92. Chung YJ, Kim HH, Kim HJ et al. RET proto-oncogene mutations are restricted to codon 634 and 618 in Korean families with multiple endocrine neoplasia 2A. Thyroid 2004: 14 (10): 813-818.
93. Sanso GE, Domene HM, Garcia R et al. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers. Cancer 2002: 94 (2): 323-330.
94. Wohllk N, Becker P, Youlton R et al. Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma. Rev Med Chil 2001: 129 (7): 713-718.
95. Puñales MK, Graf H, Gross JL et al. RET codon 634 mutations in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome. J Clin Endocrinol Metab 2003: 88 (6): 2644-2649.
96. Marsh DJ, Andrew SD, Eng C et al. Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma. Cancer Res 1996: 56 (6): 1241-1243.
97. Bartsch DK, Hasse C, Schug C et al. A RET double mutation in the germline of a kindred with FMTC. Exp Clin Endocrinol Diabetes 2000: 108: 128-132.
98. Klein I, Ésik O, Homolya V et al. Molecular genetic diagnostic program of multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma syndromes in Hungary. J Endocrinol 2001: 170: 661-666.
99. Foppiani L, Forzano F, Ceccherini I et al. Uncommon association of germline mutations of RET proto-oncogene and CDKN2A gene. Eur J Endocrinol 2008: 158 (3): 417-422.
100. Rodriguez JM, Balsalobre M, Ponce JL et al. Pheochromocytoma in MEN 2A syndrome. Study of 54 patients. World J Surg 2008: 32: 2520-2526.
101. Ong DS, Lakhani V, Oates JA Jr et al Kindred With prominent corneal nerves associated with a mutation in codon 804 of RET on chromosome 10q11. Arch Ophthalmol 2010: 128 (2): 247-249.
102. Mytakidis N, Vassiliou E, Liakos V et al. Mutation at codon 804 detected in a Greek kindred by screening of the RET gene in patients with medullary thyroid carcinoma. Endocrine Abstracts (2006) 11 P512. European Congress of Endocrinology (April) 2006.
103. Menko FH, Van Der Luijt RB, De Valk IA et al. Atypical MEN type 2B associated with two germline RET mutations on the same allele not involving codon 918. J Clin Endocrinol Metab 2002: 87 (1): 393-397.
104. Simon S, Pavel M, Hensen J et al. Multiple endocrine neoplasia 2A syndrome. Surgical management. J Pediatr Surg 2002: 37: 897-900.
105. Zakrzewska A, Makowska AM, Bar-Andziak E. 2004: Late onset of medullary thyroid carcinoma with bilateral adrenal pheochromocytomas in the case of patient with MEN 2. Pol Merkur Lekarski 17: 633-637.
106. Wohllk N, Cote GJ, Bugalho MM et al. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1996: 81: 3740-3745.
107. Oriola J, Pa'ramo C, Halperin I et al. Novel point mutation in exon 10 of the RET proto-oncogene in a family with medullary thyroid carcinoma. Am J Med Genet 1998: 78: 271-273.
108. Siggelkow H, Melzer A, Nolte W et al. Presentation of a kindred with familial medullary thyroid carcinoma and Cys611Phe mutation of the RET proto-oncogene demonstrating low grade malignancy. Eur J Endocrinol 2001: 144: 467-473.
109. Beck O, Fassbender WJ, Beyer P et al. Pheochromocytoma in childhood: implication for further diagnostic procedures. Acta Paediatr 2004: 93: 1630-1634.
110. Lindskog S, Nilsson O, Jannson S et al. Phenotypic expression of a family with multiple endocrine neoplasia type 2A due to a RET mutation at codon 618. Br J Surg 2004: 91: 713-718.
111. Neocleous V, Passalaris T, Spanou E et al. Description of the first two seemingly unrelated Greek Cypriot families with a common C618R RET proto-oncogene mutation. Genet Testing 2004: 8: 163-168.
112. Quayle FJ, Fialkowski EA, Benveniste R et al. Pheochromocytoma penetrance varies by RET mutation in MEN 2A. Surgery 2007: 142: 800-805.
113. Pasini B, Rossi R, Ambrosio MR et al. RET mutation profile and variable clinical manifestations in a family with multiple endocrine neoplasia type 2A and Hirschsprung's disease. Surgery 2002: 131: 373-381.
114. Machens A, Schneyer U, Holzhausen HJ et al. Emergence of medullary thyroid carcinoma in a family with the Cys630Arg RET germline mutation. Surgery 2004: 136: 1083-1087.
115. Dourisboure RJ, Belli S, Domenichini E et al. Penetrance and clinical manifestations of non-hotspot germline RET mutation, C630R, in a family with medullary thyroid carcinoma. Thyroid 2005: 15: 668-671.
116. Machens A, Dralle H. DNA-based window of opportunity for curative pre- emptive therapy of hereditary medullary thyroid cancer. Surgery 2006: 139: 279-282.
117. Gill JR, Reyes-Mu'gica M, Iyengar S et al. Early presentation of metastatic medullary carcinoma in multiple endocrine neoplasia, type IIA: implications for therapy. J Pediatr 1996: 129: 459-464.
118. Karga HJ, Karayianni MK, Linos DA et al. Germ line mutation analysis in families with multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma. Eur J Endocrinol 1998: 139: 410-415.
119. Bütter A, Gagné J, Al-Jazaeri A et al. Prophylactic thyroidectomy in pediatric carriers of multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma: mutation in C620 is associated with Hirschsprung's disease. J Pediatr Surg 2007: 42 (1): 203-206.
120. Aiello A, Cioni K, Gobbo M et al. The familial medullary thyroid carcinoma- associated RET E768D mutation in a multiple endocrine neoplasia type 2A case. Surgery 2005: 137: 574-576.
121. Fitze G, Schierz M, Bredow J et al. Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations. Ann Surg 2002: 236: 570-575.
122. Frank-Raue K, Heimbach C, Rondot S et al. Genotype-phenotype correlation in hereditary medullary thyroid carcinoma. Dtsch Med Wochenschr 2003: 128: 1998-2002.
123. Rodien P, Jeunemaitre X, Dumont C et al. Genetic alterations of the RET proto-oncogene in familial and sporadic pheochromocytomas. Horm Res 1997: 47: 263-268.
124. Tamanaha R, Camacho CP, Ikejiri ES et al. Y791F RET mutation and early onset of medullary thyroid carcinoma in a Brazilian kindred: evaluation of phenotype-modifying effect of germline variants. Clin Endocrinol (Oxf) 2007: 67 (5): 806-808.
125. Fugazzola L, Cerutti N, Mannavola D et al. Multigenerational familial medullary thyroid cancer (FMTC): evidence for FMTC phenocopies and association with papillary thyroid cancer. Clin Endocrinol 2002: 56: 53-63.
126. Margraf RL, Crockett DK, Krautscheid PM et al. Multiple endocrine neoplasia type 2 RET protooncogene: repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations. Hum Mutat 2009: 30 (4): 548-556.
127. Machens A, Dralle H. Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma. World J Surg 2007: 31 (5): 957-968.